StemCell Therapy

Yan Wang,1,* Yingru Zhang,1,* Gang Cai,1 Qi Li1,2

1Department of Medical Oncology & Cancer Institute of Integrative Medicine, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, Peoples Republic of China; 2Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Qi Li Email qili@shutcm.edu.cn

Abstract: In recent years, it has been found that exosomes can be used as nanocarriers, which can be used in the treatment of tumors by carrying contents. The exosomes are derived from the secretion of the organisms own cells and are characterized by a phospholipid bilayer structure and a small particle size. These characteristics guarantee that the exosomes can carry a wide range of tumor drugs, deliver the drug to the cancer, and reduce or eliminate the tumor drug band. The toxic side effects were significantly eliminated; meanwhile, the therapeutic effects of the drug on the tumor were remarkably improved. This paper reviewed the strategies and drugs presented by different scholars for the treatment of tumors based on the drugs carried by exosomes.

Keywords: exosomes, nanocarriers, function, tumor therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the rest here:
Exosomes as Actively Targeted Nanocarriers for Cancer Therapy | IJN - Dove Medical Press

This entry was posted on June 23, 2020 at 8:45 am and is filed under Integrative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |